Abstract
BACKGROUND
Neoplastic meningitis (NM), a metastatic complication of both primary central nervous system and systemic cancer, occurs in 1โ5% of patients with known cancer. Currently available treatment options are limited and provide only modest benefit. The current study was performed to determine the toxicity and response rate of intraโcerebrospinal fluid (CSF) alpha interferon (ฮฑโIFN) in the treatment of patients with NM.
METHODS
Twenty two patients (median age, 56 years) with clinical and cytologically documented NM received intraโCSF ฮฑโIFN. Tumor histologies included: lung (five patients); brain (five patients); nonโHodgkin lymphoma (three patients); breast (three patients); melanoma (two patients); chronic myelogenous leukemia (two patients); colon (one patient); and prostate (one patient). Concurrent involvedโfield radiotherapy (12 out of 22 patients) or systemic chemotherapy (11 out of 22) was administered based on clinical indications. โฮฑโIFN was administered at a fixed dose (1 ร 10^6^ IU every other day given three times per week for four weeks by induction). Patients were evaluated by CSF cytology and neurologic examination at the conclusion of induction therapy. Responding patients continued to receive ฮฑโIFN with monthly evaluations.
RESULTS
Ten out of 22 patients (45%) treated with ฮฑโIFN had a cytologic response and either stable or improved neurologic status at the conclusion of induction. Duration of response ranged from 8 to 40 weeks (median, 16 weeks). Toxicity was manifested as transient chemical arachnoiditis (16 out of 22 patients; 60% of all treatment cycles) and chronic fatigue (20 out of 22 patients). No treatmentโrelated hospitalizations or deaths were seen.
CONCLUSIONS
ฮฑโIFN has modest activity against NM. However, it is associated with considerable toxicity at the dose and schedule used in the current study and, as a result, may prove difficult to administer. Cancer 2002;94:2675โ80. ยฉ 2002 American Cancer Society.
DOI 10.1002/cncr.10547